Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have a body mass index (BMI) ≥27.0 kilogram/square meter (kg/m ²)
Are either
* individuals ≥40 years of age with established cardiovascular disease (CVD).
* CVD is defined as meeting at least one of the following:
* Coronary artery disease
* Cerebrovascular disease
* Peripheral arterial disease OR
* individuals without established CVD but have the presence of cardiovascular (CV) risk factors (primary prevention)
* women 55-69 years of age or men 50-64 years of age with at least 3 risk factors like tobacco use, dyslipidemia, hypertension at screening, or
* women ≥70 years of age or men, ≥65 years of age with at least 2 risk factors at screening.
You may not be if
Have type 1 diabetes (T1D) or (T2D), history of ketoacidosis, or hyperosmolar state/coma
Have laboratory evidence diagnostic of diabetes mellitus at screening of HbA1c ≥6.5% (≥48 millimole/mole (mmol/mol) or fasting glucose (FG) ≥126 milligram/deciliter (≥7.0 millimole/liter (mmol/L).
Any one of the following CV conditions within 90 days prior to screening
* MI
* acute coronary syndrome
* stroke
* coronary or peripheral arterial revascularization procedure, which may also include carotid artery revascularization, or
* acute decompensated heart failure
Have a known clinically significant gastric emptying abnormality such as severe gastroparesis or gastric outlet obstruction or have undergone or currently planning any gastric bypass (metabolic) surgery or restrictive bariatric surgery. Note: Liposuction or abdominoplasty are not considered as gastric bypass procedures.
Have a history of chronic or acute pancreatitis
Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Have acute or chronic hepatitis, or clinical signs or symptoms of any other liver disease, or have elevated liver enzyme measurements, determined by the central laboratory at screening
Have a presence or history of malignant neoplasms within the past 5 years prior to screening.
Clareo Health | A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
